The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.

This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.

Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Provided herein are compositions and methods for the treatment or prevention of viral infections via the use of chemical substances administered in a combinatory fashion for the suppression, inhibition, and elimination of viral loads. These compositions and methods use a glycolysis inhibitor (e.g., 2-deoxy-D-glucose (2-DG)) in combination with one or more compounds comprising one or more aromatic rings and at least one alkylamino.sub.(C≤12) group or substituted alkylamino.sub.(C≤12) group.

Disclosed herein are methods of using polyunsaturated fatty acids and derivatives thereof (“PUFAs”) to modulate I.sub.ks channels to treat conditions associated with a disruption in I.sub.ks channel activity, such as cardiac arrhythmias. In particular, disclosed herein are negatively charged PUFAs having decreased pK.sub.a values, which can activate (i.e., open) I.sub.Ks channels, and positively charged PUFAs that can inhibit (i.e., close) I.sub.KS channels.

The invention provides a method for anticoagulation, including administering to a subject in need a therapeutically effective amount of pharmaceutical composition including formula (I) or its isomers as its parent form, and its salt, ester or solvate. The invention also provides a method for anticoagulation, including administering to a subject in need a therapeutically effective amount of pharmaceutical composition including formula (I) or its isomers as its parent form, and its salt, ester or solvate for at least 1 hour, wherein a dose of the pharmaceutical composition is in an amount of about 5×10.sup.−5 mL/kg or more of body weight of the subject.

##STR00001##

The invention provides a method for anticoagulation, including administering to a subject in need a therapeutically effective amount of pharmaceutical composition including formula (I) or its isomers as its parent form, and its salt, ester or solvate. The invention also provides a method for anticoagulation, including administering to a subject in need a therapeutically effective amount of pharmaceutical composition including formula (I) or its isomers as its parent form, and its salt, ester or solvate for at least 1 hour, wherein a dose of the pharmaceutical composition is in an amount of about 5×10.sup.−5 mL/kg or more of body weight of the subject.

##STR00001##